Wren Appoints Bart Henderson as Chief Executive Officer
Wren Therapeutics has appointed Bart Henderson as the new Chief Executive Officer. With extensive experience in biotechnology, including co-founding Rhythm (Nasdaq: RYTM), he aims to advance Wren's innovative drug discovery platform targeting toxic protein intermediates related to neurodegenerative diseases. Under the leadership of outgoing CEO Samuel Cohen, Wren has made significant progress in drug discovery, focusing on Alzheimer’s and Parkinson’s diseases. Henderson's experience is expected to strengthen the company's pipeline as they move towards clinical applications.
- Bart Henderson's extensive leadership experience in biotechnology.
- Significant advancements in drug discovery for Alzheimer’s and Parkinson’s diseases.
- Potential for enhanced value creation under new leadership.
- Concerns regarding continuity with the departure of founding CEO Samuel Cohen.
Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of
Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines),
“On behalf of the Board of Directors and our investors, I want to thank Dr.
“I am excited and highly energized to lead and work alongside this outstanding team at Wren and to build on what has already been accomplished with the Company’s proprietary technology platform for previously intractable diseases,” commented
About Wren
Wren is a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. We have built a unique drug discovery platform to assay and target the transient protein intermediates in these disease pathways, the oligomers, to interrupt the molecular mechanisms that are the source of oligomer generation with small molecule therapeutics. We are focusing this platform first on two of the greatest unmet medical needs of our time: Alzheimer’s disease and Parkinson’s disease. For more information, please visit www.wrentherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220304005036/en/
Wren Therapeutics
communications@wrentherapeutics.com
Source: Wren Therapeutics
FAQ
Who is the new CEO of Wren Therapeutics?
What is Bart Henderson's experience related to Wren Therapeutics?
What progress has Wren Therapeutics made under its new leadership?
What are the main targets of Wren Therapeutics' drug discovery platform?